Bank of New York Mellon’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
HFF
TWM
N
AA
TGIA
YIH
Bank of New York Mellon's CADL Position: Q2 2026 in Review
Bank of New York Mellon increased its Candel Therapeutics (CADL) stake by 41% in Q2 2026, buying an estimated $419K and bringing the position to 191,701 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.
Bank of New York Mellon first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 52 funds tracked by Wall St. Rank hold CADL as of Q2 2026.
- Bank of New York Mellon held 191,701 shares of Candel Therapeutics worth $1.97M as of Q2 2026.
- Bank of New York Mellon bought 55,435 Candel Therapeutics shares in Q2 2026, an estimated $419K.
- Candel Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2959 holding.
- Bank of New York Mellon first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
- 52 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.